Jesús María Hernández-Rivas at University of Salamanca - Research Interests, Publications & Academic Profile

Jesús María Hernández-Rivas

Universidad de Salamanca

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Korean students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Biostatistics

60%

Cell Biology

30%

Hematology

70%

Cancer Genetics

60%

Genomic Instability

50%

Medical Science

40%

Mutagenesis

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions

Article Link

Year:

2023

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Article Link

Year:

2023

Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8

Article Link

Year:

2023

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Article Link

Year:

2023

CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML

Article Link

Year:

2022

A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling.

Article Link

Year:

2022

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia.

Article Link

Year:

2022

ALL-268 Genetic Classification of B-Cell Precursor Adult Acute Lymphoblastic Leukemia Patients Enrolled in LAL19 Trial from the Pethema Group: Response to Treatment and Survival

Article Link

Year:

2022

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

Article Link

Year:

2022

MDS-454 SF3B1 and DNMT3A Mutations Might Play a Role in Poor Prognosis and AML Progression in Patients With Isolated del(5q) MDS

Article Link

Year:

2022

Collaborators8

María Hernández-Sánchez

Profesor Ayudante Doctor

Universidad Complutense de Madrid Facultad de Medicina

SPAIN

Ignacio García-Tuñón Llanio

Profesor Ayudante Doctor

Universidad de Alcalá

SPAIN

Oscar Molina

SPAIN

PABLO VELASCO

Department Associate Professor

University of Barcelona

SPAIN

José Rivera

SPAIN

José María Bastida

SPAIN

Francesco Cerisoli

Head of Research

NETHERLANDS

Lars Bullinger

Charité University Medicine

GERMANY

How do Korean students reach out?

Meet Kite AI